 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Unicycive Therapeutics appoints Sara Kenkare-Mitra to board of directors

Appointment adds decades of drug development experience from a seasoned executive
 Sara Kenkare-Mitra, PhD

 Sara Kenkare-Mitra, PhD

LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE...

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the Company or Unicycive), today announced that Shalabh Gupta, M.D., Chief Executive Officer was recently ...

Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series

Unicycive Therapeutics, Inc. (NASDAQ:UNCY Get Free Report) was the target of a large decline in short interest in August. As of August 15th, there was short interest totalling 80,100 shares, a decline of 53.9% from the July 31st total of 173,800 shares. Based on an average trading volume of 128,500 ...

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 53.9% in August

Unicycive Therapeutics (NASDAQ:UNCY  Free Report) had its price objective decreased by HC Wainwright from $7.00 to $4.50 in a report published on Wednesday, MarketBeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Unicycive ...

HC Wainwright Trims Unicycive Therapeutics (NASDAQ:UNCY) Target Price to $4.50

Unicycive Therapeutics (NASDAQ:UNCY Free Report) had its target price trimmed by HC Wainwright from $7.00 to $4.50 in a research report released on Wednesday morning, MarketBeat reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Unicycive ...

HC Wainwright Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $4.50

Unicycive Therapeutics, Inc. (NASDAQ:UNCY Free Report) Equities researchers at HC Wainwright issued their Q1 2024 EPS estimates for Unicycive Therapeutics in a research note issued to investors on Wednesday, August 16th. HC Wainwright analyst E. Arce forecasts that the company will earn ($0.16) per ...

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) to Post Q1 2024 Earnings of ($0.16) Per Share, HC Wainwright Forecasts

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Unicycive Therapeutics (UNCY Research Report), Leg... Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Unicycive Therapeutics (UNCY Research Report), ...

Analysts Offer Insights on Healthcare Companies: Unicycive Therapeutics (UNCY), Legend Biotech (LEGN) and Reviva Pharmaceuticals Holdings (RVPH)

Recent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease Feedback from FDA Expected in Fall 2023 for OLC Program UNI-494 Phase 1 Trial Progressing as Planned with IND Application ...

Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update

Unicycive Therapeutics, Inc. (NASDAQ:UNCY Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 206,900 shares, a drop of 15.8% from the June 30th total of 245,800 shares. Based on an average daily volume of...

Short Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Drops By 15.8%

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Watchers	1,593
52-Wk Low	$0.4004
52-Wk High	$2.87

Market Cap	$31.62M
Volume (M)	337,155.00
52-Wk High	$2.87
52-Wk Low	$0.4004

Current Price	$0.91
Prev Close	$0.72
Open	$0.78
Dividend Yield	0.00%
50-Day Moving Average	$0.8676
Beta	0.00
Avg. Volume	59,661.57
PE Ratio	-0.46

52-Week High	$2.87
52-Week Low	$0.4004
Market Capitalization	$31.62M
EPS	-$1.97
Price to Book	-0.72
Revenue Per Employee	$135,500.00
Enterprise Value/EBITDA	-1.44

UNCY Unicycive Therapeutics Inc

About

Feed

News

Fundamentals